These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20959149)

  • 21. Mechanisms of TNFα regulation in uveitis: focus on RNA-binding proteins.
    Khera TK; Dick AD; Nicholson LB
    Prog Retin Eye Res; 2010 Nov; 29(6):610-21. PubMed ID: 20813201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
    Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
    Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for selective accumulation of V beta 8+ T lymphocytes in experimental autoimmune uveoretinitis induced with two different retinal antigens.
    Egwuagu CE; Mahdi RM; Nussenblatt RB; Gery I; Caspi RR
    J Immunol; 1993 Aug; 151(3):1627-36. PubMed ID: 8393049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.
    Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR
    Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteopontin is proinflammatory in experimental autoimmune uveitis.
    Hikita ST; Vistica BP; Jones HR; Keswani JR; Watson MM; Ericson VR; Ayoub GS; Gery I; Clegg DO
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4435-43. PubMed ID: 17003437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating anti-galectin-1 antibodies are associated with the severity of ocular disease in autoimmune and infectious uveitis.
    Romero MD; Muiño JC; Bianco GA; Ferrero M; Juarez CP; Luna JD; Rabinovich GA
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1550-6. PubMed ID: 16565391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infections and autoimmune diseases.
    Bach JF
    J Autoimmun; 2005; 25 Suppl():74-80. PubMed ID: 16278064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A clinical grading system for retinal inflammation in the chronic model of experimental autoimmune uveoretinitis using digital fundus images.
    Xu H; Koch P; Chen M; Lau A; Reid DM; Forrester JV
    Exp Eye Res; 2008 Oct; 87(4):319-26. PubMed ID: 18634784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rodent models of experimental autoimmune uveitis.
    Agarwal RK; Caspi RR
    Methods Mol Med; 2004; 102():395-419. PubMed ID: 15286397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mouse models of autoimmune uveitis.
    Klaska IP; Forrester JV
    Curr Pharm Des; 2015; 21(18):2453-67. PubMed ID: 25777760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding uveitis: the impact of research on visual outcomes.
    de Smet MD; Taylor SR; Bodaghi B; Miserocchi E; Murray PI; Pleyer U; Zierhut M; Barisani-Asenbauer T; LeHoang P; Lightman S
    Prog Retin Eye Res; 2011 Nov; 30(6):452-70. PubMed ID: 21807112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent developments in the treatment of posterior uveitis.
    Suttorp-Schulten MS; Jager MJ; Kijlstra A
    Ocul Immunol Inflamm; 1996; 4(4):207-17. PubMed ID: 22827460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of posterior noninfectious uveitis : Current situation and future developments].
    Pleyer U; Pohlmann D; Stübiger N
    Ophthalmologe; 2016 May; 113(5):380-90. PubMed ID: 27165275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapeutic strategies in autoimmune uveitis.
    Papotto PH; Marengo EB; Sardinha LR; Goldberg AC; Rizzo LV
    Autoimmun Rev; 2014 Sep; 13(9):909-16. PubMed ID: 24833504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The status and prospects of immunological research in uveitis].
    Zheng YZ
    Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):277-80. PubMed ID: 23866710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunologic mechanisms of uveitis. New targets for immunomodulation.
    Whitcup SM; Nussenblatt RB
    Arch Ophthalmol; 1997 Apr; 115(4):520-5. PubMed ID: 9109763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered suppressor-cell activities in uveitis.
    Nussenblatt RB; Cevario SJ; Gery I
    Lancet; 1980 Oct; 2(8197):722-4. PubMed ID: 6106830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uveitis: Molecular Pathogenesis and Emerging Therapies.
    Egwuagu CE; Alhakeem SA; Mbanefo EC
    Front Immunol; 2021; 12():623725. PubMed ID: 33995347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Review of the Various Roles and Participation Levels of B-Cells in Non-Infectious Uveitis.
    Zhu L; Chen B; Su W
    Front Immunol; 2021; 12():676046. PubMed ID: 34054864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blocking the inflammasome: A novel approach to treat uveitis.
    Shome A; Mugisho OO; Niederer RL; Rupenthal ID
    Drug Discov Today; 2021 Dec; 26(12):2839-2857. PubMed ID: 34229084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.